Downloaded 20 times
Uploaded byJain hospital,Mahavir Sikshan Sansthan
PPTX, PDF291 views
Glycemic Control & CV outcome study by lars bryden
CV outcome with new class of Drug SGLT2 Inhibitor specially Empagliflozin recently approved by USFDA and EMA for Treatment of long standing Type 2 diabetes with reduction in CVD Mortality,all cause mortlaity and Morbidity(Primary outcome-3 point MACE,time to Ist occurence of CV death,Nonfatal MI or Non fatal stroke and Key secondary outcome 4 point MACE:time to first occurence of MI,nonfatal stroke or hospitalisation for UA.EMPA-REG OUTCOME:further Prespecified Outcome >CV DEATH >NONFATAL MI >NONFATAL STROKE >HOSPITALISATION FOR HF >ALL CAUSE MORTALITY
